By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galena Biopharma  

310 N. State Street, Suite 208

Lake Oswego   Oregon  97034  U.S.A.
Phone: 1-503-400-7636 Fax: 1-503-400-6611



Company News
Galena Biopharma  (GALE) Completes Divestiture Of Abstral (Fentanyl) Sublingual Tablets As Part Of Strategic Focus On Its Immunotherapy Pipeline 11/20/2015 8:01:57 AM
Galena Biopharma  (GALE) Reports Third Quarter 2015 Financial Results And Announces Exclusive Focus On Its Clinical Development Programs With Planned Divestiture Of The Commercial Business 11/10/2015 8:09:02 AM
Galena Biopharma  (GALE) Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 At The Society For Immunotherapy Of Cancer (SITC) 30th Anniversary Annual Meeting 11/9/2015 8:23:22 AM
Galena Biopharma  (GALE) To Present Final GALE-401 Phase II Clinical Data At The 57th American Society of Hematology Annual Meeting And Exposition 11/6/2015 6:58:49 AM
Galena Biopharma  (GALE) Appoints Bijan Nejadnik, M.D., As Executive Vice President And Chief Medical Officer 10/30/2015 7:59:03 AM
Galena Biopharma  (GALE) To Report Third Quarter Financial Results And Provide Business Update On Monday, November 9, 2015 10/26/2015 7:32:27 AM
Galena Biopharma  (GALE) To Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, And The Phase II Neuvax Data Impact On Cancer Survivorship At Two Upcoming Medical Conferences 10/22/2015 7:46:47 AM
Galena Biopharma  (GALE) Collaborates With The National Cancer Institute On A Phase II Clinical Trial With Neuvax (Nelipepimut-S) In Ductal Carcinoma In Situ Patients 9/30/2015 7:28:03 AM
Galena Biopharma  (GALE) Presents Positive GALE-301 Phase 2a Clinical Trial Data At The European Cancer Congress 2015 9/28/2015 6:31:04 AM
Galena Biopharma  (GALE) To Present GALE-301 Phase 2a Clinical Trial Data At The European Society For Medical Oncology (ESMO) 9/14/2015 6:52:06 AM